# Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

> **NCT01861197** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Squamous NSCLC

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01861197
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2015-01
- **Final completion:** —
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2013-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861197, "Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01861197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*